Davenport & CO LLC Tg Therapeutics, Inc. Transaction History

Davenport & CO LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 11, 2022	BUY	$4.57 - $8.4 $55,754 - $102,480	12,200 New	12,200 $72,000
Q4 2021 Feb 10, 2022	SELL	$15.2 - $35.51 $141,436 - $330,420	-9,305 Closed	0 $0
Q2 2021 Jul 28, 2021	BUY	$32.5 - $48.96 $650 - $979	20 Added 0.22%	9,305 $360,000
Q4 2020 Jan 13, 2021	BUY	$25.27 - $54.9 $14,782 - $32,116	585 Added 6.72%	9,285 $483,000
Q3 2020 Oct 15, 2020	SELL	$18.49 - $27.24 $36,980 - $54,480	-2,000 Reduced 18.69%	8,700 $233,000
Q2 2020 Jul 28, 2020	BUY	$8.9 - $21.84 $95,230 - $233,688	10,700 New	10,700 $208,000

338

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.23B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Davenport & CO LLC with notifications on news.